Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. Now, a monoclonal antibody, named BION-1301 (anti-APRIL), is being developed to treat patients with IgA nephropathy.
BION-1301 is a potential disease-modifying approach to prevent the formation of immune complexes that deposit in the glomeruli of the kidney, causing damage. BION-1301 was developed in a TIP Pharma consortium by prof. Jan Paul Medema and dr. Hans van Eenennaam partly at the Amsterdam UMC and is now a pipeline product of Chinook Therapeutics, which recently reported that during the phase 1 trial, healthy volunteers well-tolerated BION-1301 with no serious adverse events, a pharmacokinetic half-life of approximately 33 days. The antibody demonstrated dose-dependent pharmacodynamic effects characterized by durable reductions in serum levels of free APRIL, IgA, galactose-deficient IgA (Gd-IgA1) and IgM, with a lesser reduction in IgG. Now, BION-1301 is evaluated in patients with IgA nephropathy in a phase 1b trial.
Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.
World Congress of Nephrology 2021
The ongoing phase 1 multi-center trial was presented at World Congress of Nephrology 2021.
For more information see WCN21-0706: A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Safety and Bioavailability Study of BION-1301 Administered by Intravenous (IV) and Subcutaneous (SC) Routes.
We’re off! As part of the Biotech Booster programme, IXA is setting up the Thematic Cluster 4 ‘Diagnostics/Services’ in Amsterdam.News
Do you have an innovative idea that could positively impact tomorrow’s world?
Submit your idea and compete to win € 10,000!
Only available in Dutch. Max Nijman, oprichter van VU startup Flame Away, is verkozen als een van de 50 talenten die verschijnen in het Financieel Dagblad 50 onder de 35. Dit is een lijst waarin gekeken wordt naar jonge talenten die de wereld een stukje beter maken. Max startte drie jaar geleden met een studieproject […]News